Belite Bio, Inc
BLTE
Rangering i aksjer
#3051
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Aksjekurs
$148.24
Sist synkronisert: 2026-10-19
Markedsverdi
$5.97B
Endring (1 dag)
3.82%
Endring (1 år)
64.04%
Land
US
Handel Belite Bio, Inc (BLTE)
Kategori
Healthcare
P/B-forhold for Belite Bio, Inc (BLTE)
P/B-forhold per October 2026 TTM: 7.90
Ifølge Belite Bio, Inc sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 7.90. Ved slutten av 2023 hadde selskapet et P/B-forhold på 13.45.
P/B-historikk for Belite Bio, Inc fra 2020 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 7.90 | -40.18% |
| 2024 | 13.21 | -1.78% |
| 2023 | 13.45 | -7.28% |
| 2022 | 14.51 | -185.83% |
| 2021 | -16.91 | 22.03% |
| 2020 | -13.85 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 6.251 | -20.89% |
US
|
|
| 13.2547 | 67.75% |
US
|
|
| 4.208 | -46.74% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -21.76% |
NL
|
